Prestige Consumer Healthcare (PBH – Research Report) received a Hold rating and a price target from D.A. Davidson analyst Linda Bolton Weiser today. The company’s shares closed last Friday at $57.21.
According to TipRanks, Bolton Weiser is a 4-star analyst with an average return of 3.5% and a 48.81% success rate. Bolton Weiser covers the Consumer Cyclical sector, focusing on stocks such as e.l.f. Beauty, Clarus, and Hasbro.
Prestige Consumer Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $79.00.
See today’s best-performing stocks on TipRanks >>
PBH market cap is currently $2.84B and has a P/E ratio of -33.83.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare, and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.
Read More on PBH:
- Prestige Consumer Healthcare to Present at Upcoming Investor Conferences
- Goody’s® Introduces New “GET TO GOOD™” Marketing Campaign
- Dramamine® Eases Americans’ Travel Woes with ‘Ditch the Drama’ Sweepstakes Offering a Vacation to Anywhere in the World
- Prestige Consumer Healthcare Inc. Reports Record Fiscal Year 2023
- Prestige Consumer Healthcare (PBH) Q4 Earnings Cheat Sheet
